Continues Successful Strategy of Discovering and Investing in Breakthrough Biomedical Technologies Around the Globe
Catalio Capital Management, a leading innovative healthcare investment firm, announced the successful close of its fourth venture fund, Catalio Nexus Fund IV , with over $400M in commitments across the Fund and its related co-investment vehicles. The Fund received significant backing from current Catalio investors as well as new, global institutional investors, RIAs, foundations and endowments.
Health Technology Insights: Medicare by AMA Partners with Integrity to Support Multilingual Agents
The fundraise marks a significant milestone for Catalio, reinforcing investor confidence in its differentiated strategy of backing breakthrough biomedical technology companies founded by serial scientist-entrepreneurs. Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, the firm manages $2 billion in assets across its private equity, private credit, and public equities strategies.
“We are grateful for the continued confidence and strong support we received for Fund IV from both new and existing high caliber investors,” said Olga Maltseva, Partner & Head of Operations at Catalio, who oversees the firm’s marketing division. “These new funds will allow Catalio to continue taking advantage of opportunities in a historic buyer’s market in biotech, and to keep distinguishing ourselves as a leading innovative healthcare investor around the globe.”
Catalio’s core investment approach remains centered on identifying and supporting transformative healthcare companies spun out of leading academic institutions and led by repeat founders with deep scientific expertise. Its Nexus funds have backed more than 80 private companies since Catalio’s founding five years ago and have sold or taken public a number of businesses over the years, making distributions to their limited partners every year since the firm’s inception.
Health Technology Insights: NFL Star Sauce Gardner Partners with Q-Collar to Promote Athlete Safety and Brain Health
To date, Fund IV has made 16 investments, continuing the firm’s track record of partnering with world-class teams and building category-defining life sciences businesses at all stages, from inception to IPO and beyond.
“We continue to see many compelling investment opportunities in this current market, including deals with prospects for near-term liquidity and deals with prospects for long-term growth,” said Dr. Diamantis Xylas, Partner & Head of Research at Catalio. “We are proud to invest in breakthrough biomedical technology companies developing drugs, devices, diagnostics, and tools that have potential for broad clinical impact and can enhance the lives of millions of patients around the world while delivering meaningful returns for our investors,” he said.
Recent highlights in Fund IV include:
- Co-leading PinkDx’s $40 million Series A fundraise aimed at developing diagnostics for gynecological cancers, building on Catalio’s extensive track record of success in cancer diagnostics.
- Investing in the Series A financing of Superluminal Medicines, augmenting Catalio’s portfolio of AI-enabled drug discovery companies.
- Launching two new companies focused on immunology and inflammation: Rhapsogen, co-founded by Catalio Venture Partner Dr. Jeffrey Ravetch at Rockefeller University; and TBD Pharma, co-founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins University.
- Taking advantage of attractive valuations in late-stage companies by participating in the $150M Series E financing for Imperative Care, a medical device company; a PIPE for Protara Therapeutics (NASDAQ:TARA), an oncology company; and the $180M Series D financing for Alentis Therapeutics, a company developing antibody drug conjugates (ADC) for oncology indications.
Health Technology Insights: LifeSource and InVita Healthcare Technologies Announce Launch of iTransplant
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
